ArticleDiabetes care2012
Adiponectin and all-cause mortality in elderly people with type 2 diabetes.
Article in Diabetes care, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Risk of all-cause and CHD mortality in women versus men with type 2 diabetes: a systematic review and meta-analysis.European journal of endocrinology · 2019Pooled it
- Palaeolithic diet decreases fasting plasma leptin concentrations more than a diabetes diet in patients with type 2 diabetes: a randomised cross-over trial.Cardiovascular diabetology · 2016Trial
- The Cardioprotective Effects of Adiponectin in Diabetes.Current diabetes reports · 2025Review
- Fat talks first: how adipose tissue sets the pace of aging?Life medicine · 2025Review
- Comorbidity burden may explain adiponectin's paradox as a marker of increased mortality risk in hemodialysis patients.Scientific reports · 2021Article
- Elevated levels of adiponectin associated with major adverse cardiovascular and cerebrovascular events and mortality risk in ischemic stroke.Cardiovascular diabetology · 2020Observational
- Adipokines and Aging: Findings From Centenarians and the Very Old.Frontiers in endocrinology · 2019Review
- Article
- The role of adipokines as prognostic factors of one-year mortality in hip fracture patients.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2017Article
- Elevated adiponectin but varied response in circulating leptin levels to falciparum malaria in type 2 diabetics and non-diabetic controls.Biomedical journal · 2016Article
- Evidence of a causal relationship between high serum adiponectin levels and increased cardiovascular mortality rate in patients with type 2 diabetes.Cardiovascular diabetology · 2016Article
- Adiponectin/resistin levels and insulin resistance in children: a four country comparison study.International journal of pediatric endocrinology · 2015Article
- Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients.Oncology · 2015Article
- Circulating adiponectin and cardiovascular mortality in patients with type 2 diabetes mellitus: evidence of sexual dimorphism.Cardiovascular diabetology · 2014Article
- Adiponectin & inflammatory biomarkers in coronary artery disease.The Indian journal of medical research · 2014Article
- The relationship between visceral adiposity and left ventricular diastolic function: results from the Baltimore Longitudinal Study of Aging.Nutrition, metabolism, and cardiovascular diseases : NMCD · 2013Article
- Comment on: Singer et al. Adiponectin and all-cause mortality in elderly people with type 2 diabetes. Diabetes Care 2012;35:1858-1863.Diabetes care · 2013Article
- The U-shaped Relationship of Traditional Cardiovascular Risk Factors and Adverse Outcomes in Later Life.Aging and disease · 2012Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo assess the association between serum adiponectin level and all-cause mortality in people with type 2 diabetes. Because of the insulin-sensitizing, anti-inflammatory, and antiatherogenic effects of adiponectin, we hypothesized that higher adiponectin level would be associated with lower all-cause mortality. RESEARCH DESIGN AND
methodsA total of 609 men and women aged 72 ± 6.3 years with type 2 diabetes and information on total and high molecular weight adiponectin were followed for a median of 5 years. The longitudinal association between adiponectin and all-cause mortality was analyzed with Cox proportional hazards models with time from adiponectin measurement to death as the time-to-event variable. Analyses were adjusted for demographic variables and significant diabetes parameters, significant cardiovascular parameters, and significant diabetes medications.
resultsTotal and high molecular weight adiponectin were highly correlated. The highest adiponectin quartile was strongly associated with higher all-cause mortality compared with the lowest quartile (hazard ratio = 4.0 [95% CI: 1.7-9.2]) in the fully adjusted model. These results did not change in analyses stratified by sex and thiazolidinedione use, after exclusion of people who died within one year of adiponectin measurement, or when change in weight before adiponectin measurement was considered.
conclusionsContrary to our hypothesis, higher adiponectin level was related to higher all-cause mortality. This association was not explained by confounding by other characteristics, including medications or preceding weight loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.